JCM
KRTX

JS Capital Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

JS Capital Management’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3,100
Closed -$240K – 204
2020
Q3 		$240K Buy
+3,100
New +$264K 0.01% 113

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

JS Capital Management's KRTX Position: Q4 2020 in Review

JS Capital Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q4 2020, closing a stake of 3,100 shares — an estimated $240K sold.

JS Capital Management first reported a position in KRTX in Q3 2020 and held it in 1 quarter. The position peaked at $240K in Q3 2020. 143 funds tracked by Wall St. Rank hold KRTX as of Q4 2020.

  • JS Capital Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • JS Capital Management sold 3,100 Karuna Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $240K.
  • JS Capital Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • JS Capital Management's Karuna Therapeutics, Inc. Common Stock position peaked at $240K in Q3 2020.
  • 143 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q4 2020.

Based on JS Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.